AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery

Stopped NCI decided to terminate ABTC Consortium due to NCI moving in different direction for Brain Cancer - official close date is 10/31/23

Conditions

• Brain and Central Nervous System Tumors

Interventions

• DRUG: BGB 324 (before surgery)
• DRUG: BGB 324 (after surgery)

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

• [object Object]
• [object Object]